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Personalized therapyComplement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effective, but associ-
ated with high costs. Complement inhibition monitoring in these patients has not been standardized. In this
study we evaluated novel functional assays for application in routine follow-up.
We documented that the Wieslab® complement screen assay showed a sensitivity of 1–2% of C5 activity by
adding puriﬁed C5 or normal human serum to a C5 deﬁcient serum. All the patient samples obtained during
the treatment course, were completely blocked for terminal complement pathway activity for up to four
weeks after the eculizumab infusion. Levels of complexes between eculizumab and C5were inversely correlated
to the complement activity (p= 0.01). Moreover, titrating serum from eculizumab-treated patients into normal
serum revealed that eculizumab was present in excess up to four weeks after infusion.
Thus, we demonstrate sensitive, reliable and easy-performed assays which can be used to design individual
eculizumab dosage regimens.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The atypical form of the hemolytic uremic syndrome (aHUS) has a
poor prognosis with up to 50% of cases progressing to end stage renal
disease and up to 25% of lethal outcomes in the acute phase. Comple-
ment dysregulation leading to glomerular endothelial cell damage is
considered to be a central element in aHUS etiology [1,2].
The complement system, a part of the innate immune system, can
be activated through three pathways: the classical (CP), the lectin
(LP), and the alternative (AP) [3,4]. Currently, genetic variants in AP
are identiﬁed in 50–60% of aHUS patients. Furthermore, the presence ofP, classical pathway; LP, lectin
dministration; EMA, European
inuria; C5D, C5 deﬁcient; NHS,
c acid; MBL, mannose-binding
mplexes.
y, Oslo University Hospital, P.B.
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nes).
. This is an open access article underautoantibodies against factor H or genetic variants of thrombomodulin
are associated with aHUS pathogenesis [5–17].
Eculizumab (Soliris®) is a monoclonal antibody that binds to C5 and
prevents its cleavage into C5a and C5b, thereby completely blocking the
formation of terminal complement complex (C5b-9). It is currently ap-
proved by the Food and Drug Administration (FDA) and European
Medicines Agency (EMA) for the treatment of paroxysmal nocturnal
hemoglobinuria (PNH) and aHUS andhas opened a new era in the treat-
ment of these diseases [18–23]. However, the optimal or individualized
treatment schedule has not yet been established due to lack of reliable
and easy routine tests to monitor the treatment.
The current therapy scheme is split into two phases: the initial phase
(up to four weeks for patients with ≥40 kg body mass), followed by the
maintenance phase. For pediatric patients (b18 years old and b40 kg),
dosage regimen is adjusted to their body mass; the other patients re-
ceive the same amount of the drug according to the standardized
adult treatment schedule. The present EMA and FDA guidelines recom-
mend a life-long therapy with eculizumab infusions every two weeks
(three weeks for the smallest infants) in themaintenance phase to pre-
vent aHUS relapses. This recommendation has been questioned inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patients receiving eculizumab treatment that were included in the study.
Patient
number
aHUS genetic change Gender
(F/M)
Age at
time of study (years)
P1 Factor H: c.1778T N A, p.Leu593Stop F 28
P2 Unknown M 2
P3 Unknown M 9
P4 Unknown M 12
P5 Factor H: c.2572T N A, p.Trp858Arg F 22
P6 Factor H: c.2120delC F 44
P7 C3: c.481C N T, p.Arg161Trp F 32
P8 Factor B: c.967A N G, p.Lys323Glu F 21
P9a Unknown F 13
a STEC-HUS patient.
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small, risk of meningococcal infection and sepsis [24,25], possible im-
munological complications in the long term, including development of
neutralizing antibodies, and the extremely high cost of this treatment.
Although approval of eculizumab signiﬁed new hope for the aHUS
patients, available reports describing pharmacokinetic and pharmaco-
dynamics of this drug remain limited. Thus, in this study we aimed to
establish a monitoring regimen for patients treated with eculizumab
using novel and reliable complement assays that can be used routinely
to follow the complement activity in these patients with high degree
of sensitivity and speciﬁcity. This approach presents a highly relevant
tool to develop individual treatment protocols for patients receiving
complement inhibition therapy.
2. Materials and methods
2.1. Study population
All nine patients included in the study received eculizumab treat-
ment at the Departments of Pediatric Nephrology and Nephrology of
the Radboud UniversityMedical Center as recommended by the current
EMA and FDA guidelines. In several patients the treatment was
discontinued or longer intervals between infusions were chosen as
indicated.
The genetically C5 deﬁcient (C5D) donor, included in the study as a
control, has previously been described [26]. A normal human serum
(NHS) pool was made using serum samples from 20 healthy adult vol-
unteers. Puriﬁed human C5 was obtained from Quidel (San Diego, CA).
The study was approved by the institutional review board of the
Radboud University Medical Center and was performed in accordance
with the appropriate version of the Declaration of Helsinki. Informed
consent of all patients and/or their parents as well as of the healthy
volunteers was obtained before analysis.
2.2. Sample collection
Whole blood was allowed to clot at room temperature for 30–45 min
(serumsamples) or immediately placed on ice (ethylenediamineteraacetic
acid (EDTA) plasma samples). Serum and EDTA plasma samples were
prepared by centrifugation within 1 h after whole blood collection
(10 min, 2500 ×g, 4 °C), aliquoted and stored at−80 °C. Urine samples
were collected and centrifuged (10 min, 2500 ×g, 4 °C), supernatants
were aliquoted and stored at−80 °C.
2.3. Assays to detect complement activity
The Wieslab® complement system screen (Euro Diagnostica AB,
Malmö, Sweden) was used according to the manufacturer's protocol.
This kit detects serum complement activity through CP, LP and AP
with C5b-9 as common detection system for all three pathways. Due
to the high degree of mannose-binding lectin (MBL) deﬁciency in the
population, which gives a low LP activity, we included only the CP and
AP assays of this kit in the present study. These assays were tested for
sensitivity using a C5 deﬁcient serum and were used to analyze serum
samples from patients before, during and after treatment with
eculizumab. In addition, serum samples from eculizumab-treated
patients were diluted in NHS and analyzed in these assays.
The soluble C5b-9 (sC5b-9) levels in urine samples were measured
using electroluminescent epitope assay as described before [27].
2.4. Assay to detect eculizumab–C5 complexes
The eculizumab and C5 (E–C5) complexes were detected in serum
and urine samples using an enzyme-linked immunosorbent assay as de-
scribed in detail previously [28]. In several cases serum samples werenot available, then the E–C5 complexesweremeasured in EDTAplasma,
as indicated in footnote of Table 2.
2.5. Statistical analysis
Statistical analyses were performed using one-way ANOVA and un-
paired two-tailed t-test. Spearman's rank test was used for correlation
testing.
3. Results
3.1. Characterization of the patient group
Nine patients were included in the study, eight with aHUS (P1–8)
and onewith STEC-HUS (P9) (Table 1). The STEC-HUS patientwas diag-
nosed by detection of antibodies against serotype O157. This patient
received a single eculizumab infusion, based on the severe clinical
symptoms and non-bloody diarrhea at presentation. Six patients
(P1–P5 and P9) were receiving eculizumab therapy during the time of
the study, of whom four started during the study period and therefore
had a baseline sample included (P1, P3, P4, P9). Therapy of three pa-
tients (P6, P7, and P8) was already discontinued and only one single
sample from each of these was collected (Table 2). The dosage regimen
was in general applied according to the EMA and FDA guidelines (every
week initially and then every second week on maintenance), but in pa-
tients P1, P4, and P5 the intervals between the eculizumab infusions
were extended late in the maintenance phase from three to six weeks.
From the patients that discontinued therapy or received eculizumab
treatment with extended time intervals, none suffered from aHUS
recurrence.
3.2. Sensitivity of the complement activity assay to detect functionally
active C5
A useful assay to monitor the complement inhibitory effect of
eculizumab requires a high degree of sensitivity for C5 activity at low
C5 concentrations in order to ﬁnd the optimal time-point for the next
infusion. Therefore, we ﬁrst analyzed the sensitivity of the Wieslab®
complement system screen test with respect to detection of small
amounts of free and functionally active C5. For this purpose we used
serum from a C5 deﬁcient (C5D) individual, added puriﬁed C5 protein
or NHS as C5 source, at increasing concentrations, andmeasured recov-
ery of complement activity (Fig. 1). C5D serum supplemented with pu-
riﬁed C5 at two-fold steps (1 μg/mL–512 μg/mL) showed recovery of
complement activity, asmeasured both by the CP and AP assay, at levels
of approximately 10 μg C5/mL serum (Fig. 1A and B). C5D serum was
then supplementedwithNHS (1%–100% of the total volume) and recov-
ery activity was measured (Fig. 1C and D). Detectable recovery started
already at 1–2% of addedNHS in both the CP and theAP assay, indicating
that both these assays are highly sensitive to detect even trace amounts
of C5 present.
Table 2
Treatment schedule and complement activity proﬁles in nine eculizumab-treatedpatients.
Treatment stage CPa (%) APb (%) E–C5c (μg/mL)
P1
before dose 1u 105 64 0
1 week after dose 1 (900 mg)u 4.3 0.2 87
1 week after dose 2 (900 mg)u 1.9 0.7 169
1 week after dose 3 (900 mg)u 1.4 0.1 187
1 week after dose 4 (900 mg)u 0.9 0 137
2 weeks after dose 5 (1200 mg)u 0.5 0.1 121
2 weeks after dose 6 (1200 mg) 0.5 0 118
2 weeks after dose 14 (1200 mg) 0.6 0.2 133
3 weeks after dose 15 (1200 mg) 1.0 0.3 133
4 weeks after dose 16 (1200 mg) 1.4 0.2 122
P2
2 weeks after dose 6 (300 mg) 0.1 0 107
2 weeks after dose 8 (300 mg) 0.2 0 90
2 weeks after dose 9 (300 mg) n.a. n.a. 97
2 weeks after dose 11 (300 mg) 0 0 99
2 weeks after dose 13 (300 mg) 0 0 99
2 weeks after dose 15 (300 mg) 0.1 0 91
P3
before dose 1 87 76 0
1 week after dose 1 (900 mg) 0.6 0.1 67
1 week after dose 3 (900 mg) 0.3 0 107
1 week after dose 4 (900 mg) n.a. n.a. 87
2 weeks after dose 5 (1200 mg) 0 0 76
2 weeks after dose 6 (1200 mg) 0.1 0 93
2 weeks after dose 9 (1200 mg) 0 0 146
P4
before dose 1 n.a. n.a. 0
1 week after dose 1 (900 mg) n.a. n.a. 111
1 week after dose 2 (900 mg) 0.2 0 120
1 week after dose 3 (900 mg) 0 0 183
2 weeks after dose 6 (1200 mg) 0 0 87
2 weeks after dose 8 (1200 mg) 0.1 0 96
2 weeks after dose 11 (1200 mg) 0 0 91
3 weeks after dose 12 (1200 mg) 0 0 63
P5
2 weeks after dose 6 (1200 mg)u 0.9 0 193
2 weeks after dose 7 (1200 mg)u 0.7 0 99
2 weeks after dose 8 (1200 mg) 0.8 0.4 101
2 weeks after dose 9 (1200 mg)u 0.6 0 89
2 weeks after dose 10 (1200 mg)u 0.6 0 110
2 weeks after dose 11 (1200 mg) 1.0 0.1 132
3 weeks after dose 12 (1200 mg) 1.8 0.5 144
4 weeks after dose 13 (1200 mg) 2.2 0.4 127
6 weeks after dose 15 (1200 mg) 73 45 48
P6
14 weeks after dose 10 (1200 mg) 92 20 0
P7
8 weeks after dose 10 (1200 mg) 107 81 37
P8
23 weeks after dose N50 (1200 mg) 65 8.3 0
P9 STEC-HUS
before dose 1 91 104 0
1 week after dose 1 (600 mg) 4.0 2.1 77
5 weeks after dose 1 77 89 18
n.a.: serum sample not available (EDTA plasma sample was used to measure E–C5).
a CP = classical complement pathway activity.
b AP = alternative complement pathway activity.
c E–C5 = complexes between eculizumab and C5.
u Urine samples were measured for these treatment points.
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To analyze the effect of eculizumab in the patients, we quantiﬁed the
complement activity with the Wieslab® assay (Table 2). The comple-
ment system was completely blocked by eculizumab in all samples ob-
tained one or two weeks after infusion (AP b 3% in all, CP b 5% in all).Notably, this was also the case in samples obtained three and four
weeks after infusion (P1, P4, and P5). However, in the samples obtained
ﬁve weeks after infusion (P9) or longer (P5, P6, P7, and P8), recovery of
complement activity was observed.
E–C5 complexes in the baseline samples were not detectable, and in
samples with complete complement inhibition they were consistently
high (median 107 μg/mL, total range of 63–193 μg/mL) (Table 2). How-
ever, when complement activity recovered, the amount of E–C5 com-
plexes decreased. Thus, in the samples, taken at ﬁve to eight weeks
after the last dose (P5, P7, P9) E–C5 complexes were signiﬁcantly (p b
0.001) decreased (range 18–48 μg/mL) compared to those with com-
plete inhibition. After 14 and 23weeks (P6 and P8) theywere undetect-
able. Therewas a signiﬁcant (r=−0.38; p=0.01) negative correlation
between the complement activity measured by AP and the amount of
E–C5when all samples were included. The complement activity obtain-
ed with CP and AP correlated closely (r = 0.83; p b 0.0001).
3.4. Estimation of eculizumab in excess in serum samples from
aHUS patients
To examine the excess of eculizumab in serum samples during treat-
ment, we selected samples from ﬁve patients that were obtained four
weeks or less after an eculizumab infusion; i.e. they showed complete
inhibition in theWielisa® assays (Fig. 2).Weperformed careful titration
of patient samples with increasing NHS concentrations to observe re-
covery of the terminal pathway using the CP and AP assays (Fig. 2).
Since no effect of NHS was seen when added in an amount less
than 80% of the total volume, only the range of 80–95% NHS is shown
(i.e. 5–20% patient serum). Serum from the C5D individual (without
eculizumab) was used as control. Adding NHS to C5D serum induced a
recovery fully consistent with what would be expected if there was no
C5 inhibitor present (Fig. 2). CP recovered in the range of 78–91% and
AP in the range of 93–112% when added NHS constituted 80–95% of
the ﬁnal volume.
The patient samples showed a substantially delayed recovery com-
pared to the C5D control, consistent with free eculizumab in excess.
Thus, when 80% NHS and 20% patient serumwas used, complement ac-
tivitywas inhibited in all samples, except for one (P1, oneweek after the
ﬁrst dose). All samples obtained in the maintenance phase two weeks
after the eculizumab infusion required at least 90% NHS to reach a re-
covery of complement activity above 10%. In two of these samples
(the second samples of P3 and P4) complement activity remained
below 10% after supplementation with 95% NHS. Samples taken four
weeks after the infusion (P1 and P5) required more than 80% NHS for
complement recovery.
Thus, our results indicate the presence of excessive eculizumab in
aHUS patients, which may bind and inactivate fresh C5 added with
NHS. In this case, increase in E–C5 complexes would be expected upon
addition of NHS to the patient sera. In order to test this hypothesis, we
measured E–C5 complexes in the samples. Indeed, levels of E–C5 com-
plexes consistently increased with addition of NHS to the samples,
conﬁrming binding of added C5 to free eculizumab (Fig. 3).
3.5. sC5b-9 and E–C5 complexes measured in urine
We ﬁnally investigated whether E–C5 complexes can be found in
urine. Normally, large proteins are not secreted via the kidneys due to
their size, however, aHUS patients often have proteinuria and therefore
may have E–C5 present in urine. The molecular weights of E–C5 com-
plexes are 340 and 530, dependent on monovalent or bivalent binding
of C5. Available urine samples from patients P1 and P5, with high
E–C5 complexes in plasma were tested and no E–C5 complexes were
detected in urine samples. However, in a urine sample obtained from
P1 before treatment, sC5b-9 was detected at the level of 63.5 CAU/L,
indicating improved effect on renal function after eculizumab treatment
was initiated.
Fig. 1. Recovery of complement activation in serum from a C5 deﬁcient donor. Serum from a C5D donor was supplemented with the commercially available puriﬁed C5 at two-fold
concentrations steps (1 μg/mL–512 μg/mL) (A and B) or with normal human serum (NHS) at 1%–100% of the total volume (C and D). Activity of classical (A and C) and alternative
(B and D) pathways was measured. Data are presented as percentage of activation of the positive control (100%) provided with the assay. The experiments were repeated three times
and representative curves are shown.
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In this study, we have documented a high degree of sensitivity of the
complement activity screen test. We have used in vitro assays to evalu-
ate the efﬁcacy of the treatment on complement activity, and demon-
strated an excess of eculizumab in samples obtained up to four weeks
after drug infusion. In the samples taken ﬁve weeks or longer after an
eculizumab infusion, recovery of complement activity was detected,
which correlated with decreased levels of the E–C5 complexes. Further
studies in larger cohorts should indicate whether proﬁles that we ob-
served are characteristic for all patients, especially children. Collectively,
these data support the current tests to be suitable as a guide for individ-
ualized treatment of patients that receive eculizumab.
The sensitivity and speciﬁcity of the screen test was documented
using C5D serum. Small amounts of puriﬁed C5 and NHS increased the
activity in C5D from zero. Only 1–2% NHS added increased the activity,
indicating a very high sensitivity of the assay. By using puriﬁed C5,
slightly more protein had to be added to get an increase, which is
consistent with the puriﬁed protein being less functionally active than
native C5 present in serum. This was supported by the fact that 100%
recovery was obtained by addition of NHS, whereas 70% was the maxi-
mum recovery obtained by puriﬁed C5, which had to be added several-
folds the normal serum concentration in order to obtain this recovery.
Puriﬁed C5 obtained from other source (Complement Technology)
also was not able to fully reconstitute complement activity (data not
shown). Using such C5 preparations may give inaccurate and
underestimated results when interpreting eculizumab inhibiting capac-
ity for C5. Nevertheless, in the future in clinical practice commercially
available C5 may be used as an internal control to standardize the
assay, especially to compare results between the laboratories. Thus,
we proceeded with NHS as a C5 source and supplemented serum
samples from ﬁve patients with various concentrations of NHS and
measured complement activity. The results clearly indicate that in themaintenance phase of the therapy all the samples obtained two weeks
after the eculizumab infusion required supplementation with at least
10 volumes of NHS to produce detectable recovery of complement
activity. One sample, however, differed from the others (the sample
of P1 that was obtained one week after the ﬁrst eculizumab infusion).
This sample showed 4.3% CP activity, though 0.2% AP activity
(Table 2), and required less NHS for recovery (Fig. 2) than the others.
This may indicate individual differences in requirement for full satura-
tion of circulating C5 at ﬁrst dose given. After the second dose, samples
from this patientwere comparable to the others. For thewholematerial
there was, however, a very close correlation between results obtained
with CP and AP was seen. Thus, it is possible that in the future only
one of these is needed, but more data are needed in order to compare
these two and decide which test should be chosen. We have followed
a girl on eculizumab treatment over a couple of years with N35 samples
tested for CP and AP activity, and all samples in both assays consistently
showed b1% activity (personal observation, TEM). The LP assay would
not be suitable for this particular purpose, due to the high frequency
of MBL deﬁciency in the population.
So far, it is not clear, whether discontinuation of therapy is a good
choice for all recovered aHUS patients. Recent reports indicate that
somepatients experience relapses after treatment has beendiscontinued,
while others do not [29–31]. Nevertheless, at this point it is crucially im-
portant to introduce individualized complement inhibition therapy for
aHUS patients, especially in maintenance phase. This should be done in
terms of treatment intervals and also in terms of eculizumab dosage.
Our data suggest that a majority of patients receive substantially more
drug than needed for complete C5 inhibition.
Current guidelines on eculizumab treatment prescribe the same
dose regimen for all adults (≥18 years of age), independent of such
factors as age, body mass and C5 concentration in blood. Individual ap-
proach to dose regimen, based on the novel assay protocol, described
here, would optimize quantity of the drug needed and indicate most
Fig. 2. Recovery of complement activation in eculizumab-treated aHUS serum samples. Samples from ﬁve aHUS patients and a C5 deﬁcient donor were supplemented with NHS (range
80–95% of the total volume), after that the recoveries of the classical and the alternative complement pathways were analyzed by the Wieslab® complement system screen. Data are
represented as percentage of activation of the positive control provided with the assay by the manufacturer.
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analyzed for eculizumab inhibiting capacity using our titration assays
and, in case considerable excess will be established, intervals may be
extended by one week at a time or dosage can be adjusted in case of
absence of signs of active disease. This will relieve the economic
pressure on the health care system, making this very expensive—andvery promising—medication more easily available also to other patients
who are in need of it.
One previous study has used the Wieslab® kit to monitor aHUS pa-
tients [32]. They used doses of eculizumab in the range of 12–33 mg/kg
(12 mg/kg corresponds to the normal ﬁrst dose of 900 mg given to a
75 kg person). They showed a recovery in some patients after three
Fig. 3. Increase of the levels of E–C5 complexes with addition of NHS to serum samples
from eculizumab-treated aHUS patients. Samples from patients P1 (after dose 1 and
dose 5), P2 (after dose 6 and dose 13), P3 (after dose 1 and dose 5), and P4 (after dose 2
and dose 8) were diluted with various amounts of NHS, and the levels of E–C5 complexes
were measured. The data are presented as mean and standard deviation. Statistically
signiﬁcant increases between the dilution steps with p b 0.05 (*) and p b 0.01 (**) are
indicated.
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study the excess of eculizumab or the E–C5 complexes were not inves-
tigated. Despite this, and the difference in dosage and complement ac-
tivity recovery time, their data support the screen test as a suitable
test to monitor these patients. Our test regimen, however, gives more
detailed data on the activity and the excess of eculizumab present at
the time of sampling.
In a recent comprehensive study Noris et al. [33] investigated in
detail complement activation proﬁle in aHUS patients treated with
eculizumab. They showed that endothelial cell deposition of C5b-9 in-
duced from these patients could beused as a tool tomonitor eculizumab
therapy. This assay is interesting from a pathophysiological point of
view and documents that if there is sufﬁcient eculizumab present in
serum there is markedly reduced deposition of C5b-9 on the cells.
Thus, this is an important assay approach, but it requires a specialized
laboratory experienced with endothelial cell work and this assay is far
more demanding with respect to personal and economical resources
as compared to the simple assayswe here describe. Ourmethods are in-
dependent on personal skills, can be performed at every hospital where
ELISA equipment is established and the results can be available for the
patient's physician the same day as the patient visit the clinic.
In a very recent study PNH patients treated with eculizumab over a
two-year period were followed with serum analysis of CH50 and free
eculizumab [34]. These data are in accordance with ours, but it should
be noted that due to batch-to-batch variation in quality of erythrocytes,
the traditional hemolytic CH50 assay is prone to variability in lower de-
tection range, which might be clinically signiﬁcant. Thus, a more accu-
rate detection of low level activity in the 1% range will be obtained
with the standardized ELISA-based assay we have used.
Another study suggested the use of novel highly speciﬁc antibody
against soluble C5b to monitor in vitro complement activation blockade
by eculizumab. The authors used hemolytic assay to activate comple-
ment in this experiment. In the future, it might be interesting to test
whether the use of soluble C5b marker will contribute to better
standardization of our assay based on Wieslab® complement system
screen test [35].In conclusion, we have documented sensitive, reliable and easy to
perform routine assays to be used as a platform for a therapy regimen
that optimizes the use of eculizumab for individualized treatment.
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